- Conditions
- Advanced Solid Tumors
- Interventions
- M7437
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Huntersville, North Carolina • Galveston, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Cancer
- Interventions
- Xevinapant, IMRT, Placebo
- Drug · Radiation
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Precemtabart tocentecan, Bevacizumab, Trifluridine/Tipiracil (FTD-TPI)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 19
- States / cities
- Lone Tree, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 16 more
- Conditions
- Dermatomyositis, Polymyositis
- Interventions
- M5049 dose, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- M1774, Niraparib
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Austin, Texas • Dallas, Texas + 1 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine Tablets
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 66
- States / cities
- Cullman, Alabama • Mobile, Alabama • Little Rock, Arkansas + 58 more
- Conditions
- Multiple Myeloma
- Interventions
- M3258, M3258 20 mg
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Hackensack, New Jersey + 1 more
- Conditions
- BRAF V600E-mutant Metastatic Colorectal Cancer
- Interventions
- Encorafenib, Binimetinib, Cetuximab, Irinotecan, Folinic Acid, 5-Fluorouracil
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 90
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more
- Conditions
- BRAF V600E-mutant Metastatic Colorectal Cancer
- Interventions
- encorafenib, Binimetinib, Cetuximab
- Drug
- Lead sponsor
- Pierre Fabre Medicament
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- New York, New York • Germantown, Tennessee
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Data Collection
- Other
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 662 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer
- Interventions
- TRX518, Cyclophosphamide, Avelumab
- Drug
- Lead sponsor
- Leap Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Colorectal Cancer
- Interventions
- M9140, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Encinitas, California • Fresno, California • Providence, Rhode Island + 3 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo
- Biological · Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 49
- States / cities
- Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more
- Conditions
- Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
- Interventions
- Nirogacestat
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Orlando, Florida • Tampa, Florida + 10 more
- Conditions
- Healthy, Hepatic Impairment
- Interventions
- Mirdametinib (MEK Inhibitor)
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
- Interventions
- Mirdametinib (PD-0325901) oral capsule or dispersible tablet
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Ovarian Cancer
- Interventions
- M6620, Avelumab, Carboplatin
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 7
- States / cities
- Greenbrae, California • Stamford, Connecticut • Saginaw, Michigan + 3 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Refractory or Relapsed Solid Tumors, Lymphoma
- Interventions
- Avelumab
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • The Bronx, New York
- Conditions
- Coronavirus Disease 2019
- Interventions
- M5049, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
- Conditions
- Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
- Interventions
- Avelumab, Irinotecan, Paclitaxel, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 28
- States / cities
- Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT)
- Drug · Radiation
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 21
- States / cities
- Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Cisplatin, Carboplatin, Pemetrexed, Nab-paclitaxel, Gemcitabine, Docetaxel, M7824, Bintrafusp alfa, Paclitaxel
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Fountain Valley, California • San Marcos, California • Port Saint Lucie, Florida + 5 more